{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:28:54Z","timestamp":1787009334485,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In clinical trials, tocilizumab (TCZ) is efficacious in patients with giant cell arteritis (GCA). This study evaluated the real-world tolerability and effectiveness of TCZ in Japanese patients with GCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicentre, prospective, Phase 4, large-scale, observational study, patients with GCA (with no TCZ treatment 6\u2009months before the study) were recruited from 71 centres across Japan. Patients received subcutaneous TCZ 162\u2009mg weekly (observation period, 52\u2009weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 117 patients [female, 70.1%; mean age, 74.2\u2009years; mean disease duration, 1.4\u2009years; treated for new-onset GCA, 71.8%; presence of large-vessel lesions (LVLs), 61.5%; previous immunosuppressant use, 28.2%; glucocorticoids at baseline, 95.7% (mean: 22.4\u2009mg\/day)], 38.5% reported adverse events. The most common adverse events of special interest were neutropaenia and leukopaenia (7.7%), followed by serious infection (6.0%). The relapse-free proportion was 85.0%; relapse after remission, 6.0%; and no remission, 9.0%. At the last observation, 94.2% of relapse-free patients received a concomitant glucocorticoid dose of &amp;lt;10\u2009mg\/day. Fatigue, headache, neck pain, and absence of LVLs were positively associated with the relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TCZ was effective and well tolerated in Japanese patients with GCA and may be an effective treatment option combined with glucocorticoids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/road074","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T08:31:29Z","timestamp":1690792289000},"page":"775-783","source":"Crossref","is-referenced-by-count":9,"title":["A multicentre, large-scale, observational study of\u00a0tocilizumab in\u00a0patients with giant cell arteritis in\u00a0Japan"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Risk Communication Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Safety Science Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Specialty Medical Science Department, Medical Affairs Division, Chugai Pharmaceutical Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-2587","authenticated-orcid":false,"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"2024070612133469000_R1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of\u00a0vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024070612133469000_R2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 guideline on\u00a0management of\u00a0vasculitis syndrome \u2013 digest version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ J"},{"key":"2024070612133469000_R3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14397595.2018.1546358","article-title":"Pathophysiology of\u00a0large vessel vasculitis and\u00a0utility of\u00a0interleukin-6 inhibition therapy","volume":"29","author":"Yoshifuji","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024070612133469000_R4","article-title":"Handbook of\u00a0Health and\u00a0Welfare Statistics 2021","author":"Ministry of Health, Labour and Welfare"},{"key":"2024070612133469000_R5","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/road019","article-title":"Nationwide clinical and\u00a0epidemiological study of\u00a0large-vessel vasculitis in\u00a0Japan in\u00a02017","author":"Konda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024070612133469000_R6","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02171-6","article-title":"Associated factors of\u00a0poor treatment outcomes in\u00a0patients with giant cell arteritis: clinical implication of\u00a0large vessel lesions","volume":"22","author":"Sugihara","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024070612133469000_R7","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/art.11480","article-title":"Mortality of\u00a0large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in\u00a0patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2024070612133469000_R8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of\u00a0the EULAR recommendations for\u00a0the management of\u00a0large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070612133469000_R9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of\u00a0Rheumatology\/Vasculitis Foundation guideline for\u00a0the management of\u00a0giant cell arteritis and\u00a0Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024070612133469000_R10","article-title":"RoActemra","author":"European Medicines Agency"},{"key":"2024070612133469000_R11","article-title":"ACTEMRA (Tocilizumab) Injection","author":"U.S. Food and Drug Administration"},{"key":"2024070612133469000_R12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2024070612133469000_R13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of\u00a0tocilizumab in\u00a0giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2024070612133469000_R14","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1837-7","article-title":"Health-related quality of\u00a0life in\u00a0patients with giant cell arteritis treated with tocilizumab in\u00a0a phase 3 randomised controlled trial","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024070612133469000_R15","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","article-title":"New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and\u00a0extension","volume":"61","author":"Stone","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024070612133469000_R16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228697","article-title":"Complete resolution of\u00a0giant cell arteritis after tocilizumab monotherapy determined by positron emission tomography-CT","volume":"12","author":"Akagi","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2024070612133469000_R17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0218492320960866","article-title":"Repetitive aortic dissection in\u00a0a patient with giant cell arteritis","volume":"29","author":"Motoji","year":"2021","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"2024070612133469000_R18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/rheumatology\/kez511","article-title":"Tocilizumab monotherapy for\u00a0large vessel vasculitis: results of\u00a0104-week treatment of\u00a0a prospective, single-centre, open study","volume":"59","author":"Saito","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024070612133469000_R19","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez138","article-title":"Large vessel giant cell arteritis suggested by magnetic resonance imaging of\u00a0the thigh: a potential mimicker of\u00a0myositis, fasciitis and\u00a0skeletal muscle vasculitis","volume":"58","author":"Kadoba","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024070612133469000_R20","first-page":"541","article-title":"Effect of\u00a0tocilizumab on\u00a0neutrophils in\u00a0adult patients with rheumatoid arthritis: pooled analysis of\u00a0data from phase 3 and\u00a04 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024070612133469000_R21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for\u00a0the treatment of\u00a0rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024070612133469000_R22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of\u00a0tocilizumab on\u00a0neutrophil function and\u00a0kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"2024070612133469000_R23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40744-019-0139-5","article-title":"Adverse events in\u00a0giant cell arteritis and\u00a0rheumatoid arthritis patient populations: analyses of\u00a0tocilizumab clinical trials and\u00a0claims data","volume":"6","author":"Gale","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2024070612133469000_R24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for\u00a0lower intestinal perforations in\u00a0patients with rheumatoid arthritis treated with tocilizumab in\u00a0comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024070612133469000_R25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001417","article-title":"Efficacy and\u00a0safety of\u00a0tocilizumab in\u00a0giant cell arteritis: a single centre NHS experience using imaging (ultrasound and\u00a0PET-CT) as a diagnostic and\u00a0monitoring tool","volume":"6","author":"Sebastian","year":"2020","journal-title":"RMD Open"},{"key":"2024070612133469000_R26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs\u00a0placebo for\u00a0the treatment of\u00a0giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in\u00a0a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024070612133469000_R27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02480-4","article-title":"Vision loss in\u00a0patients with giant cell arteritis treated with tocilizumab","volume":"23","author":"Amsler","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024070612133469000_R28","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221113747","article-title":"Tocilizumab in\u00a0visual involvement of\u00a0giant cell arteritis: a multicenter study of\u00a0471 patients","volume":"14","author":"Loricera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024070612133469000_R29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in\u00a0giant cell arteritis. Observational, open-label multicenter study of\u00a0134 patients in\u00a0clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024070612133469000_R30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in\u00a0giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024070612133469000_R31","article-title":"Association between the patterns of\u00a0large-vessel lesions and\u00a0treatment outcomes in\u00a0patients with large-vessel giant cell arteritis","author":"Sugihara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024070612133469000_R32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and\u00a0acute-phase reactant levels at giant cell arteritis flare in\u00a0a randomized trial of\u00a0tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road074\/51618583\/road074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/775\/58463049\/road074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/775\/58463049\/road074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T08:14:57Z","timestamp":1720253697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/4\/775\/7234005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7,31]]},"published-print":{"date-parts":[[2024,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road074","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,7,31]]}}}